Vikash Oza, MD, provides clinical insight for Case 2, a 7-year-old female patient with atopic dermatitis.
Joshua Zeichner, MD: Let’s open this up to the group. Based on the patient’s age, the location of the rash, and the challenges associated with her treatment plan, what do you guys recommend?
Vikash Oza, MD: One thing in this case is the significant involvement of facial dermatitis. For people who see adults, maybe that’s something we see a lot. But in a 7-year-old who has such significant facial involvement and then only limited involvement on the extremities, it isn’t the most common prototype of a patient you’d see. That would make me wonder whether a contactant could be involved here. This has become increasingly common, even in our field of pediatric dermatology.
Before prescribing systemic agents, should we be evaluating and ruling out allergic contact dermatitis? There are certain scenarios—persistent hand dermatitis, unusual facial dermatitis—where maybe the first step is to take a step back and say: “Is there a contactant in your skin care products?” There’s a lot of exposure for children who are chronically using multiple skin care products. Then there is an increasing use of “organic” skin care products and essential oils. The number of different contactants that they’re exposed to has also increased. That might be my first step. Is what you’re looking at a pure flare of their underlying atopic dermatitis? Or is there a component of allergic contact dermatitis involved in their presentation? It’s important to take that step back when you’re seeing children who have less prototypical involvements.
Joshua Zeichner, MD: That’s such a good point, because if there’s an allergic contact dermatitis component, then putting them on a biologic medication for atopic dermatitis isn’t necessarily going to be an effective treatment, because you’re constantly exposed to that allergic contact allergen.
Vikash Oza, MD: Potentially. It also sometimes depends on the contactant. But I totally agree. When you have a suspicion, it might be something that you want to rule out.
Transcript edited for clarity
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
Lebrikizumab improves AD symptoms for adolescents inadequately controlled with cyclosporine
October 17th 2023Of the patients that responded to lebrikizumab at week 16 in the phase 3 trials ADvocate 1 and ADvocate 2, 84% achieved a clinically meaningful response in at least 1 domain of the disease (mild signs, symptoms, or quality of life impact) at 52 weeks.
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
October 13th 2023A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
September 20th 2023Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.